The HemOnc Pulse

Dr. Garcia-Manero on the Data Behind the Luspatercept Approval

Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, live at the Eleventh Annual Meeting of the Society of Hematologic Oncology to discuss the phase III COMMANDS trial, the recent approval of luspatercept, and other developments in myelodysplastic syndromes (MDS) treatment and research.
Dr. Garcia-Manero spoke about the design of the phase III COMMANDS trial, which evaluated luspatercept versus epoetin alfa for the treatment of anemia in patients with lower-risk MDS who required red blood cell (RBC) transfusions but had not previously received an erythropoiesis-stimulating agent.
“The study is very interesting in that it's very well controlled … and the data [are] very clear,” he said.
The phase III trial showed 58.5% of patients receiving luspatercept achieved the primary endpoint of RBC transfusion independence for at least 12 weeks with a mean hemoglobin increase of at least 1.5 g/dL within the first 24 weeks, while this was only reported in 31.2% of patients receiving epoetin alfa.

Mazyar Shadman, MD, MPH, Reports the Latest BTKi News in CLL

Dr. Shadman of the Fred Hutchinson Cancer Center in Seattle rounds up the latest news in chronic lymphocytic leukemia (CLL) from the summer conferences, including updates on novel Bruton tyrosine kinase inhibitor (BTKi) therapies in CLL.

Bhavana Bhatnagar, MD, on the Molecular Revolution in AML

In this episode of The HemOnc Pulse, Dr. Bhatnagar, an Associate Professor of Medicine at the West Virigina University Cancer Institute, reflects on how the molecular characterization of acute myeloid leukemia (AML) has evolved. She joins host Chadi Nabhan, MD, MBA, FACP, to discuss how this growing base of knowledge has impacted diagnosis, treatment, and classification.
“The most significant changes have come about as a result of improvements and refinements in the molecular characterization of AML,” Dr. Bhatnagar said.
Some of these changes include major updates in the World Health Organization and European LeukemiaNet systems.
The episode also highlights Dr. Bhatnagar’s recent research, which explored the differential impact of mutations by race in patients with AML. While questions remain, she outlined future research that may help explain some disparities in AML outcomes.

Do Venetoclax Combinations Trump Chemotherapy in Frontline CLL Treatment?

Is there a venetoclax combination that reigns supreme in chronic lymphocytic leukemia (CLL)? Is venetoclax-based therapy the way to go in treating frontline CLL? Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, shares his thoughts on these questions and recent data published in the New England Journal of Medicine.

Why Grzegorz Nowakowski, MD, Says There’s a ‘Revolution’ in LBCL Therapy

Dr. Nowakowski, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic, talks about the revolution in treatment options in diffuse large B-cell lymphoma(DLBCL).
"The last couple of years, we've seen quite a revolution in the treatment of DLBCL," he said. "We have multiple approved therapies now, and more coming, so it's really a very rapidly changing field."
He also discusses the five-year follow-up data from the L-MIND study, which evaluated tafasitamab in combination with lenalidomide.

An Expert’s Look into the World of Rare Blood Cancers

Naveen Pemmaraju, MD, Associate Professor at the University of Texas MD Anderson Cancer Center, talks about the rare, ultrarare, and forgotten blood cancers, including his lifelong work in blastic plasmacytoid dendritic cell neoplasm (BPDCN), in this episode of The HemOnc Pulse.

The Logistics of CAR-T in Hematologic Malignancies

Navneet Majhail, MD, MS, the Physician in Chief at Sarah Cannon in Nashville, Tennessee, delves into the intricacies of chimeric antigen receptor (CAR) T-cell therapy, discussing the logistics and challenges involved with these therapies.
Dr. Majhail explores strategies to improve access to CAR-T therapy and he discusses the role of CAR-T amidst the availability of bispecific antibodies as treatments for blood cancers.

Abi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost Effective

Drs. Vijenthira and Prica, both of the Princess Margaret Cancer Centre, speak with host Chadi Nabhan, MD, MBA, FACP, about their analysis on the cost-effectiveness of pola-R-CHP and second-line CAR-T in patients with DLBCL, and why its results differed from a similar study published in the journal Blood in December 2022.

Sagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MM

Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain approaches to minimal residual disease (MRD) in MM are “premature,” and the data that show why sustained MRD negativity is key, with host Chadi Nabhan, MD, MBA, FACP.

Alan Skarbnik, MD, Gives the Lowdown on Treating Patients with Follicular Lymphoma

Alan Skarbnik, MD, of Novant Health, discusses treating patients with follicular lymphoma, the nuances involved in those decisions, and why bispecifics are here to stay, with host Chadi Nabhan, MD, MBA, FACP.